Gen Surg Vivas · surgical-critical-care
Massive transfusion in the bleeding surgical patient — trigger, ratio, TXA, fibrinogen and calcium
Fellowship viva on surgical massive transfusion: MTP triggers and scores, PROPPR ratios with dynamic nuance, CRASH-2 TXA timing, CRYOSTAT-2 fibrinogen restraint, calcium under citrate load, whole-blood selection and early VTE vigilance.
On this page
Study tools
Target exams
Write your answer
Saved on this device. No marking — you are the marker.
Examiner probes
- He is hypotensive with a positive FAST and 2 units running. Activate or wait — and with what score, ratio, sequence and speed?[6][1][25][8]
- Injury was 75 minutes ago. TXA — dose, timing numbers, and what happens if you miss the window?[2][3][4]
- Fibrinogen for everyone or for the low — and calcium with every round? Defend both with the trials.[10][11][14][16]
- Whole blood or components for this pressure — and what do you watch for after haemostasis?[19][9][21][24]
Model responses
1. Activate now — 1:1:1 fast with plasma early, scored formally. Hypotension with active bleeding and blood running meets clinical triggers, and 1 to 3 units in trigger-meeting patients carry no excess harm signal — activation is the safe error direction.[9] Formalise it: TASH most validated, ABC without laboratories, shock index on vitals with fair performance — 45 articles, 11 validated scores.[6] Give 1:1:1 plasma-platelets-red cells during active resuscitation (PROPPR: 338 vs 342, exsanguination 9.2% vs 14.6%, haemostasis 86% vs 78%, 23 complications equal), sequence plasma early (red-cell-first carries worse adjusted mortality), and deliver fast — shorter time to blood means better outcomes, within the 1:1:1 to 1:1:2 protocol range.[1][25][8]
2. TXA 1 g now — inside every window that matters. Give 1 g loading over 10 minutes then 1 g over 8 hours: CRASH-2 all-cause 14.5% vs 16.0% (RR 0.91), bleeding death 4.9% vs 5.7% (RR 0.85).[2] At 75 minutes he sits in the best gradient band — within 1 hour RR 0.68, 1 to 3 hours RR 0.79, after 3 hours harm RR 1.44 — and inside the pooled optimal criterion of within 2 hours of injury.[3][4] Missing the window converts benefit to harm: after 3 hours TXA is not merely useless but suspect, so the dose travels with the first blood, never after the operation.
3. Fibrinogen targeted, calcium routine. No empirical cryoprecipitate for every activation: 3 pools (6-g equivalent) within 90 minutes gave 28-day death 25.3% vs 26.1% with equal thrombosis, and five randomised trials total 24% vs 25% (OR 1.03) — replace documented hypofibrinogenaemia with bleeding only.[10][11] Calcium is the opposite: measure ionised levels every round, because plasma raised hypocalcaemia (1.0 or less) to 53% vs 36% with survival tied to severe lows — while arrival means of 1.08 regardless prove shock contributes too, so replace by level under citrate load.[14][16]
4. Whole blood first at this pressure — then restraint plus VTE vigilance. At systolic pressure 84 he is inside the verified benefit subgroup (below-90 aOR 0.72, below-70 aOR 0.64) against no overall adjusted difference — offer low-titre O whole blood first where available, 1:1:1 otherwise, naming the observational limit.[19] After haemostasis: stop escalating (small volumes carry no excess signal, large ones do worse), run limited-volume hypotensive resuscitation only where brain injury is absent (in-hospital 6.3% vs 16.3%), and start VTE prophylaxis at haemostasis — 13% VTE with early PE dominance in the first 72 hours.[9][24][21]
References16ShowHide
- [1]Holcomb JB, Tilley BC, Baraniuk S, et al. Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial. JAMA, 2015.PMID 25647203
- [2]Shakur H, Roberts I, Bautista R, et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet, 2010.PMID 20554319
- [3]Roberts I, Shakur H, Afolabi A, et al. The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. Lancet, 2011.PMID 21439633
- [4]Osawa I, Goto T, Roberts I, et al. Tranexamic acid for trauma: optimal timing of administration based on the CRASH-2 and CRASH-3 trials. Br J Surg, 2025.PMID 40277024
- [6]Shih AW, Al Khan S, Wang AY, et al. Systematic reviews of scores and predictors to trigger activation of massive transfusion protocols. J Trauma Acute Care Surg, 2019.PMID 31454339
- [8]Meneses E, Boneva D, McKenney M, et al. Massive transfusion protocol in adult trauma population. Am J Emerg Med, 2020.PMID 33071074
- [9]Gelbard RB, Griffin RL, Reynolds L, et al. Over-transfusion with blood for suspected hemorrhagic shock is not associated with worse clinical outcomes. Transfusion, 2022.PMID 35753037
- [10]Davenport R, Curry N, Fox EE, et al. Early and Empirical High-Dose Cryoprecipitate for Hemorrhage After Traumatic Injury: The CRYOSTAT-2 Randomized Clinical Trial. JAMA, 2023.PMID 37824155
- [11]Burt T, Guilliam A, Cole E, et al. Effect of early administration of fibrinogen replacement therapy in traumatic haemorrhage: a systematic review and meta-analysis of randomised controlled trials with narrative synthesis of observational studies. Crit Care, 2025.PMID 39875966
- [14]Moore HB, Tessmer MT, Moore EE, et al. Forgot calcium? Admission ionized-calcium in two civilian randomized controlled trials of prehospital plasma for traumatic hemorrhagic shock. J Trauma Acute Care Surg, 2020.PMID 32317575
- [16]Rushton TJ, Tian DH, Baron A, et al. Hypocalcaemia upon arrival (HUA) in trauma patients who did and did not receive prehospital blood products: a systematic review and meta-analysis. Eur J Trauma Emerg Surg, 2024.PMID 38319350
- [19]Torres CM, Stolarski AE, Kenzik KM, et al. Identifying trauma patients who benefit from whole blood transfusion: An effect decomposition analysis on patient survival. Transfusion, 2025.PMID 40717387
- [21]Myers SP, Brown JB, Leeper CM, et al. Early versus late venous thromboembolism: A secondary analysis of data from the PROPPR trial. Surgery, 2019.PMID 31230842
- [22]Nguyen M, Pirracchio R, Kornblith LZ, et al. Dynamic impact of transfusion ratios on outcomes in severely injured patients: Targeted machine learning analysis of the Pragmatic, Randomized Optimal Platelet and Plasma Ratios randomized clinical trial. J Trauma Acute Care Surg, 2020.PMID 32520897
- [24]Indorewala Y, Nasef Y, Jayagopi K, et al. Permissive hypotension in adult trauma: A systematic review of outcomes across clinical settings, injury type, and resuscitation strategies. Am J Emerg Med, 2026.PMID 42030689
- [25]Hynes AM, Westein RJ, Turner TJ, et al. Fresh frozen plasma-first approach is independently associated with improved survival in severely injured patients undergoing massive transfusion. J Trauma Acute Care Surg, 2026.PMID 42275580